A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 42-49

  Joensuu, Greetta ^a,b   Joensuu, Timo ^b   Nokisalmi, Petri ^a,c   Reddy, Chandana ^d   Isola, Jorma ^e   Ruutu, Mirja ^c   Kouri, Mauri ^b   Kupelian, Patrick A ^f   Collan, Juhani ^c   Pesonen, Sari ^a,c   Hemminki, Akseli ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b International Comprehensive Cancer Center Docrates   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TAMPERE   (Finland)

^f M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Chemotherapy; EGFR targeted therapy; Gefitinib; Nonmetastatic prostate cancer; Radiotherapy

Indexed keywords

CORRELATIVE STUDY; DOSE LIMITING TOXICITY; EGFR TARGETED THERAPY; EPIDERMAL GROWTH FACTOR RECEPTORS; GEFITINIB; HORMONE TREATMENT; IN-PHASE; INTERLEUKIN-1; KAPLAN-MEIER; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL RATES; PERFORMANCE STATUS; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION THERAPY; RELAPSE-FREE SURVIVAL RATES; SALVAGE THERAPY; SEMINAL VESICLE; SURVIVAL RATE; THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY; TOTAL DOSE; TUMOR NECROSIS FACTORS;

CHEMOTHERAPY; DISEASES; PATIENT MONITORING; PHOSPHORYLATION; POPULATION STATISTICS; THREE DIMENSIONAL; TUMORS;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR;

ACNE; ACUTE GASTROENTERITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOMEGALY; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DECREASED APPETITE; DERMATITIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY SKIN; DYSURIA; ECZEMA; EPISTAXIS; FATIGUE; FEVER; HEART FAILURE; HEART HYPERTROPHY; HEARTBURN; HEMATEMESIS; HEMATURIA; HUMAN; INSOMNIA; KIDNEY FAILURE; MALE; METEORISM; MYOCARDITIS; NAUSEA; NOCTURIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PROCTITIS; PROSTATE; PROSTATE CANCER; PRURITUS; RADIATION DOSE; RHINITIS; SEMINAL VESICLE; SIDE EFFECT; SKIN MANIFESTATION; SUBDURAL HEMATOMA; TASTE DISORDER; URETER STONE; URTICARIA; XEROSTOMIA;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUINAZOLINES; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951264492     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1731     Document Type: Article

References (46)

1. P.R. Dutta, and A. Maity Cellular responses to EGFR inhibitors and their relevance to cancer therapy Cancer Lett 254 2007 165 177
2. J.S. Ochs Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors Int J Radiat Oncol Biol Phys 58 2004 941 949
3. M.H. Cohen, G.A. Williams, and R. Sridhara United Sates Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218
4. E.S. Kim, V. Hirsh, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial Lancet 372 2008 1809 1818
5. P. Chinnaiyan, S. Huang, and G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
6. D. Raben, B.A. Helfrich, and D. Chan ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer Semin Oncol 29 Suppl. 4 2002 37 46
7. K. Williams, B. Telfer, and I. Stratford ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model Brit J Cancer 86 2002 1157 1161
8. F. Caponigro, C. Romano, and A. Milano A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck Anticancer Drugs 19 2008 739 744
9. C. Chen, M. Kane, and J. Song Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer J Clin Oncol 25 2007 4880 4886
10. J. Maurel, M. Martin-Richard, and C. Conill Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 66 2006 1391 1398
11. V. Valentini, A.D. Paoli, and M.A. Gambacorta Infusional 5-fluorouracil and ZD1839 (gefitinib-IRESSA) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: A phase I and II trial (1839/0092) Int J Radiat Oncol Biol Phys 72 2008 644 649
12. S. Phuphanich, J. Rudnick, and R. Chu A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM), abstract no. 2088 J Clin Oncol 26 2008
13. T.E. Stinchcombe, D.E. Morris, and C.B. Lee Induction chemotherapy with carboplatin, irinotecan and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer J Thoracic Oncol 3 2008 250 257
14. S. Ma, Y. Xu, and Q. Deng Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population Lung Cancer 60 2008 208 214
15. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
16. B. Shuch, M. Mikhail, and J. Satagopan Racial disparity of epidermal growth factor receptor expression in prostate cancer J Clin Oncol 22 2004 4725 4729
17. N. Torring, F. Dagnaes-Hansen, and B.S. Sorensen ErbBI and prostate cancer: ErbBI activity is essential for androgen-induced proliferation and protection Prostate 56 2003 142 149
18. N. Normanno, A. DeLuca, and C. Bianco Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2006 2 16
19. G. DiLorenzo, G. Tortora, and F.P. D'Armiento Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin Cancer Res 8 2002 3438 3444
20. T. Schlomm, P. Kirstein, and L. Iwers Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer Clin Cancer Res 13 2007 6579 6584
21. D.J. Chen, and C.S. Nirodi The epidermal growth factor receptor: A role in repair of radiation-induced DNA damage Clin Cancer Res 13 2007 6555 6560
22. H.P. Rodemann, K. Dittmann, and M. Toulany Radiation-induced EGFR-signaling and control of DNA-damage repair Int J Radiat Biol 83 2007 781 791
23. P. Dent, D.B. Reardon, and J.S. Park Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells leading to increased proliferation and protection from radiation-induced cell death Mol Biol Cell 10 1999 2493 2506
24. T. Akimoto, N.R. Hunter, and L. Buchmiller Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas Clin Cancer Res 5 1999 2884 2890
25. M. Sheridan, T. O'Dwyer, and C. Seymour Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck Radiat Oncol Investig 5 1997 180 186
26. R. Schmidt-Ullrich, R. Mikkelsen, and P. Dent Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation Oncogene 15 1997 1191 1197
27. R. Schmidt-Ullrich, K. Valerie, and P. Fogleman Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells Radiat Res 145 1996 81 85
28. S. Carter, K.L. Auer, and D.B. Reardon Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells Oncogene 16 1998 2787 2796
29. J.R. Grandis, S.D. Drenning, and A. Chakraborty Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro J Clin Investig 102 1998 1385 1392
30. D. Bandyopadhyay, M. Mandal, and L. Adam Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells J Biol Chem 273 1998 1568 1573
31. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
32. P. Kupelian, D. Kuban, and H. Thames Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995 Int J Radiat Oncol Biol Phys 61 2005 415 419
33. Novocastra Laboratories Ltd. NCL-EGFR. Instructions for use. 2004.
34. J. Isola, M. Tanner, and A. Forsyth Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization Clin Cancer Res 10 2004 4793 4798
35. H. Kimura, K. Kasahara, and M. Sekijima Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor gefitinib Lung Cancer 20 2005 393 399
36. C.J. Kovacs, B.M. Daly, and M.J. Evans Cytokine profiles in patients receiving wide-field plus prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate Cytokine 23 2003 151 163
37. M. Ranson, L.A. Hammond, and D. Ferry ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial J Clin Oncol 20 2002 2240 2250
38. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237 2246
39. D.B. Costa, S. Kobayashi, and D.G. Tenen Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers Lung Cancer 58 2007 95 103
40. H. Asahina, K. Yamazaki, and I. Kinoshita A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Brit J Cancer 95 2006 998 1004
41. A. Sutani, Y. Nagai, and K. Udagawa Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp Brit J Cancer 95 2006 1483 1489
42. E.J. Small, J. Fontana, and N. Tannir A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer BJU Int 100 2007 765 769
43. C.M. Canil, M.J. Moore, and E. Winquist Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group J Clin Oncol 23 2005 455 460 (Pubitemid 46224221)
44. A.L. Schwer, D.M. Damek, and B.D. Kavanagh A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas Int J Radiat Oncol Biol Phys 70 2008 993 1001
45. G.L. Gravina, C. Festuccia, and G.P. Galatioto Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer Urology 70 2007 728 733
46. E. Olapade-Olaopa, D. Moscatello, and E. MacKay Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer Brit J Cancer 82 2000 186 194